Printer Friendly

EPIGEN FILES FOR U.S. PATENT ON HUMAN CARCINOMA ANTIGEN

 WELLESLEY, Mass., Feb. 9 /PRNewswire/ -- Epigen, Inc. (AMEX: EPN), a biopharmaceutical company organized to develop and commercialize cancer therapeutics, diagnostics and imaging agents, announced today that it filed a U.S. Patent application to cover the Human Carcinoma Antigen (HCA), HCA antibodies, HCA immunoassays and novel methods of imaging and therapy.
 Epigen's Human Carcinoma Antigen was discovered by John F. Codington, Ph.D., Harvard Medical School, through research begun at Massachusetts General Hospital and continuing at Boston Biomedical Research Institute. HCA is a mucin glycoprotein. It is generally found in large quantities on the cell membranes of carcinomas (malignant tumors) but not in normal tissue. Monoclonal antibodies covered by the patent application measure and seek HCA.
 HCA was characterized by Svein Haavik, Ph.D., University of Oslo, who joins Dr. Codington as a member of Epigen's Scientific Advisory Board and as a co-inventor.
 Epigen's first three products are covered under the patent filing. The initial product is the "COD Test," named for its discover Dr. Codington. It is an in vitro (outside the body) blood test to measure the level of HCA in the bloodstream. Company research has shown that HCA is shed into the bloodstream, and that there is a correlation between the amount of HCA in the bloodstream and tumor burden.
 The COD Test is designed to measure the effectiveness of cancer treatment, and once the patient is in remission, reveal whether the cancer is recurring. Of the 1.1 million newly discovered cancer patients each year in the United States, over 900,000 or 84 percent will be diagnosed as having carcinomas.
 Epigen's COD Test is expected to be used to monitor carcinomas on a monthly basis for at least a year after treatment. Immunotech Corp., a Boston based diagnostic manufacturing firm, is formatting the COD Test and will be producing materials for clinical trials expected to begin in the first half of 1993. To expedite obtaining the data necessary for marketing approval, Epigen is focusing on one type of carcinoma, breast cancer. Clinical trials are expected to take approximately six months to complete prior to submitting product license applications to the Food and Drug Administration and European regulatory authorities.
 Simultaneously, Epigen is developing an in vivo (inside the body) imaging agent. This product consists of monclonal antibody combined with a radioactive label. Because of the specificity of the antibody to HCA, the radioactive label is designed to be carried directly to the tumor site upon injection and to mark the tumor so the tumor's location can be plotted by scintographic imaging.
 This procedure is expected to introduce a new standard for determining the location and size of the tumor. whether or not it has metastasized and the location of any metastasis. The imaging agent is also intended to be used as a post-operative check to determine if all the cancer has been removed.
 Ronald L. Van Heerturn, M.D. and director of the Department of Radiology, Columbia Presbyterian Medical Center, New York City, will be the principal investigator for the combined Phase I/II trials of the imaging agent at the center. Dr. Van Heerturn is also a member of Epigen's Scientific Advisory Board.
 The company expects to file an Investigational New Drug (IND) application in the second quarter of 1993 and start Phase I/II safety and dosimetry trials in the third quarter.
 Epigen, under the director of Soldano Ferrone, MD., Ph.D., chairman of the Department of Microbiology and Immunology, New York Medical Center, is developing a vaccine to treat carcinomas. Proprietary anti- idiotypic monoclonal antibodies are being created which are designed to act like purified HCA and activate an immune system response to attack malignant tumors. These "anti-ids" are covered by the patent application.
 The objective of Epigen's therapeutic program is to develop a vaccine to treat a broad range of human carcinomas, including breast, lung, prostrate and colon cancers. In addition to activating the body's own immune system to attack malignant tumors, it is expected to be also effective as a preventive carcinoma vaccine.
 Epigen, Inc. is developing proprietary cancer products for the health-care industry designed to be more effective, less expensive and less invasive than other products now available. The company's major products in development include the COD Test to monitor malignant tumors; a carcinoma imaging agent using Epigen's proprietary monoclonal antibody; and an anti-idiotypic antibody cancer vaccine to protect and treat a broad range of human cancers. Epigen's headquarters are located in Wellesley, Mass.
 -0- 2/9/93
 /CONTACT: James Mongiardo, president and CEO of Epigen, 617-237-9102; or William Doyle of SMS, Inc., 212-230-2177/


CO: Epigen, Inc. ST: Massachusetts IN: MTC SU:

SM-WB -- NY004 -- 4471 02/09/93 08:50 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 9, 1993
Words:781
Previous Article:PRIME HOTEL PROPERTIES TO BE SOLD IN SEALED BID SALE ON APRIL 16
Next Article:HOFFMANN-LA ROCHE TO PURSUE RESEARCH DESPITE DEMONSTRATION
Topics:


Related Articles
IDEC PHARMACEUTICALS REPORTS ON RESEARCH ADVANCE TO INCREASE DISEASE-FIGHTING POTENTIAL OF IMMUNE SYSTEM THERAPIES
IMMUNOGEN, INC. TO RECEIVE U.S. PATENT ON THE USE OF TARGETED CYTOTOXIC AGENTS FOR CANCER THERAPY
EPIGEN REPORTS 1992 FINANCIAL RESULTS
Celltech Antibody Technology Platform Further Strengthened Through New Patents in US and Europe
Therion Biologics Issued Broad U.S. Patents Covering Fundamental AIDS Vaccine Technology
Protein Design Labs Issues Patent License to Genentech for Herceptin.
Corixa Corporation Obtains Worldwide Exclusive License to Leukemia Antigen Company Plans to Use WT1 to Develop Therapeutic Vaccines for Leukemia and...
Epigen, Inc. Announces the Hiring of Ortho's Former Vice President of Research.
Medarex and Epigen Form Antibody Collaboration.
Medarex and Epigen Form Antibody Collaboration.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters